Partners with

AZ Capital acts as advisor in Miura Partners backing of Saesco Medical

AZ Capital is pleased to announce that it has acted as financial advisor in Miura Partners backing of Saesco Medical, a European leader in the distribution of devices and medical equipment for minimally invasive surgery.

Miura Partners has partnered with Saesco Medical, a European group headquartered in Barcelona, specialized in the distribution of medical devices, consumables, and equipment for minimally invasive surgery. The transaction includes the acquisition of Cardiolink, a company founded in 2004 and recognized as a leader in the implementation of medical technologies in Spain and Portugal. Cardiolink joins the Saesco group to strengthen its presence in the clinical and hospital sector in Iberia and broaden its therapeutic offering.

Founded in 2009 in Barcelona, Saesco is a benchmark in the implementation, training, and commercialization of innovative medical technologies, primarily focused on the surgical field and covering therapeutic areas such as obesity, gynecology, urology, and general surgery. The company has evolved into a multi-vertical platform with a direct presence in five countries (Spain, Belgium, the Netherlands, Italy, and Poland), and operates commercially across major European markets. Its portfolio includes over 600 medical-focused products, distributed exclusively for international manufacturers.

The company serves over 2,000 clients across Europe in both public and private sectors, offering solutions to large hospitals and specialized clinics alike. Since 2019, it has integrated six companies across Europe, reinforcing its leadership as a pan-European distributor of medical technologies. Miura’s investment—executed via a capital increase—will support Saesco’s strategy for growth and international consolidation.

Cardiolink brings a highly complementary offering in terms of product, channel, and customer base, with a strong presence in the Spanish public hospital sector. Its business is structured around key divisions such as cardiology, general surgery, endoscopy, organ preservation, urology, and gynecology—significantly expanding the group’s therapeutic coverage. Following the transaction, the combined group reaches over €50 million in revenue, consolidating its position as a key player in the European medical technology distribution market.

Sector: Healthcare and Pharma